Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

XPhyto: Innovating a Therapeutic Psychedelic Drug Pipeline

It’s been dubbed the Age of Anxiety. Yet it’s quickly becoming far worse than that. With the arrival of globalism, the new millennium has already become synonymous with the threat of deadly pandemics. And the onslaught of the worst of them s...
Marc Davis | January 20, 2021 |

Biopharma Makes Licensing Deal for Therapeutic Rights in Japan

The company's reasons for the transaction and expected short-term, stock-moving events are provided in a ROTH Capital Partners report. In a Sept. 9 research note, ROTH Capital Partners analyst Yasmeen Rahimi reported that Eidos Therapeutics Inc. (EIDX:NASDAQ) agreed...
Streetwise Reports | September 12, 2019 |

Biotech's DMD Therapeutic 'Solidifies the Ground for Potential Pivotal Design'

The latest development concerning this clinical asset and other Q2/19 highlights are provided in an H.C. Wainwright & Co. report. In an Aug. 8 research note, analyst Joseph Pantginis reviewed Capricor Therapeutics Inc.'s (CAPR:NASDAQ) Q2/19 financials and reported t...
Streetwise Reports | August 14, 2019 |

Biopharma Receives FDA Fast Track Designation for Cancer Therapeutic

An explanation of the categorization and its implications are provided in a Paradigm Capital report. In a May 30 research note, Paradigm Capital analyst Rahul Sarugaser reported that Zymeworks Inc.'s (ZYME:NYSE; ZYME:TSX) lead product candidate ZW25 wa...
Streetwise Reports | June 10, 2019 |

Biopharma's Brain Cancer Therapeutic Compelling, Its Stock Undervalued

A description of the asset and its potential are provided in a Dawson James report. In a July 11 research note, Dawson James Securities analyst Jason Kolbert reported that coverage of DelMar Pharmaceuticals Inc. (DMPI:NASDAQ) transferred to him and, subseq...
Streetwise Reports | July 19, 2019 |

'Up-to-Date' COT Report: A Maddening Déjà Vu

In life, there are a distant events from one's past that embed themselves in one's memory banks in a manner and forcefulness that is directly related to their personal or historical importance. The birth of one's first child, one's first love affair or an athletic achieve...
Streetwise Reports | March 11, 2019 |

XPhyto: The Cutting Edge of Medical Cannabis Science

At the forefront of the next wave of cannabis commercialization, is a German-focused company with headquarters in Vancouver, XPhyto Therapeutics Corp. (CSE: XPHY; FSE: 4XT) , that is building a much-coveted cannabis R&D cultivation facility in a converted nuclear bunker and o...
Marc Davis | November 12, 2019 |

InMed Shares Trade Up 25% After Becoming First to Advance Cannabinol into Clinical Trials

InMed Pharmaceuticals shares traded 25% higher after reporting that it is the first to advance cannabinol into therapeutic clinical trials. Vancouver-based clinical stage biopharmaceutical company InMed Pharmaceuticals Inc. (IN:TSX; IMLFF:OTCQX) , which is engaged in...
Streetwise Reports | January 21, 2020 |

The Great Dichotomy

One of the advantages of being a sexagenarian is that after forty years investing in stocks, bonds, commodities, and currencies you have a pretty good idea when something is not exactly "right." If you have lived a good, normal life and you still have decent control of ov...
Streetwise Reports | February 10, 2020 |

CloudMD Is My TeleHealth Stock

An entirely new—and highly profitable—industry is being borne out in 2020— TeleHealth. CloudMD Software & Services Inc. (DOC:CSE; DOCRF:OTCQB; 6PH:FSE) is my favorite way to play teleHealth. It's growing quickly with over 100,000 patients registered on its ap...
Streetwise Reports | April 29, 2020 |
1 2 3 4 5 6 7 8 9 10 ...